Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
(2023) In Leukemia and Lymphoma- Abstract
The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared... (More)
The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure.
(Less)
- author
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- epub
- subject
- keywords
- brexucabtagene autoleucel, CAR T-cell therapy, indirect treatment comparison, mantle cell lymphoma, non-Hodgkin lymphoma, standard of care
- in
- Leukemia and Lymphoma
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:37840282
- scopus:85174242231
- ISSN
- 1042-8194
- DOI
- 10.1080/10428194.2023.2268228
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2023 Kite Pharma. Published by Informa UK Limited, trading as Taylor & Francis Group.
- id
- e5ec2026-68b4-45f8-9b07-27a18b131ec3
- date added to LUP
- 2023-12-20 16:09:55
- date last changed
- 2024-04-19 01:40:18
@article{e5ec2026-68b4-45f8-9b07-27a18b131ec3, abstract = {{<p>The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure.</p>}}, author = {{Hess, Georg and Dreyling, Martin and Oberic, Lucie and Gine, Eva and Zinzani, Pier Luigi and Linton, Kim and Vilmar, Adam and Jerkeman, Mats and Chen, Jenny M.H. and Ohler, Anke and Stilgenbauer, Stephan and Thieblemont, Catherine and Lambert, Jonathan and Zilioli, Vittorio Ruggero and Sancho, Juan Manuel and Jimenez-Ubieto, Ana and Fischer, Luca and Eyre, Toby A. and Keeping, Sam and Park, Julie E. and Wu, James J. and Nunes, Ana and Reitan, John and Wade, Sally W. and Salles, Gilles}}, issn = {{1042-8194}}, keywords = {{brexucabtagene autoleucel; CAR T-cell therapy; indirect treatment comparison; mantle cell lymphoma; non-Hodgkin lymphoma; standard of care}}, language = {{eng}}, publisher = {{Taylor & Francis}}, series = {{Leukemia and Lymphoma}}, title = {{Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma}}, url = {{http://dx.doi.org/10.1080/10428194.2023.2268228}}, doi = {{10.1080/10428194.2023.2268228}}, year = {{2023}}, }